Updates on Chimeric Antigen Receptor T-Cells in Large B-Cell Lymphoma

Updates on Chimeric Antigen Receptor T-Cells in Large B-Cell Lymphoma

CD19-targeting chimeric antigen receptor (CAR) T-cells have changed the treatment paradigm of patients with large B-cell lymphoma (LBCL). Three CAR T-cells were approved by the Food and Drug Administration (FDA) for patients with relapsed and/or refractory (R/R) LBCL in the third-line setting: tisag...

Full description

Saved in:

Bibliographic Details
Main Authors:	Khalil Saleh, Nadine Khalife, Ahmadreza Arbab, Rita Khoury, Claude Chahine, Rebecca Ibrahim, Zamzam Tikriti, Nohad Masri, Mohamad Hachem, Axel Le Cesne
Format:	Article
Language:	English
Published:	MDPI AG 2024-12-01
Series:	Biomedicines
Subjects:	CD19-targeting CAR T-cells lisocabtagene maraleucel axicabtagene ciloleucel tisagenlecleucel large B-cell lymphoma
Online Access:	https://www.mdpi.com/2227-9059/12/12/2810
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Real-World Characterization of Toxicities and Medication Management in Recipients of CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma in Nova Scotia, Canada
by: Jenna Shaw, et al.
Published: (2024-12-01)

Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies
by: Haiqiong Zheng, et al.
Published: (2024-11-01)

CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA
by: Ugo Testa, et al.
Published: (2024-10-01)

From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy
by: E. Pinto, et al.
Published: (2025-01-01)

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
by: Eugenio Galli, et al.
Published: (2021-10-01)

Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma
by: Hui-Ju Hsieh, et al.
Published: (2025-03-01)

Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell administration
by: Alice Sýkorová, et al.
Published: (2024-09-01)

Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy
by: C. Carcopino, et al.
Published: (2024-12-01)

Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment
by: Rahul Navab, et al.
Published: (2025-01-01)

Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults
by: Maike Breidenbach, et al.
Published: (2025-01-01)

Advancing Chimeric Antigen Receptor T-Cell Therapy for Acute Myeloid Leukemia: Current Limitations and Emerging Strategies
by: Daniela Damiani, et al.
Published: (2024-12-01)

Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review
by: Joseph Sassine, et al.
Published: (2025-01-01)

Late onset pancytopenia post chimeric antigen receptor T cell therapy triggered by a COVID-19 vaccination: a case report
by: Nicola Maciocia, et al.
Published: (2024-11-01)

The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis
by: Jile Liu, et al.
Published: (2025-01-01)

Construction and characterization of chimeric FcγR T cells for universal T cell therapy
by: Juanjuan Zhao, et al.
Published: (2025-01-01)

Current status and innovative developments of CAR-T-cell therapy for the treatment of breast cancer
by: Hany E. Marei, et al.
Published: (2025-01-01)

CXCL10 and IL15 co-expressing chimeric antigen receptor T cells enhance anti-tumor effects in gastric cancer by increasing cytotoxic effector cell accumulation and survival
by: Siyue Nie, et al.
Published: (2024-12-01)

CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES
by: Ugo Testa, et al.
Published: (2024-02-01)

Cardiovascular toxicity of tisagenlecleucel in children and adolescents: analysis of spontaneous reports submitted to FAERS
by: Ganggang Wang, et al.
Published: (2025-01-01)

The advent of chimeric antigen receptor T Cell therapy in recalibrating immune balance for rheumatic autoimmune disease treatment
by: Qianyu Guo, et al.
Published: (2024-12-01)

Persistence of activated anti‐mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas
by: Sameer Mir, et al.
Published: (2024-11-01)

In vitro functional validation of anti-CD19 chimeric antigen receptor T cells expressing lysine-specific demethylase 1 short hairpin RNA for the treatment of diffuse large B cell lymphoma
by: Zhi Guo, et al.
Published: (2025-01-01)

A preclinical study of allogeneic CD19 chimeric antigen receptor double‐negative T cells as an off‐the‐shelf immunotherapy drug against B‐cell malignancies
by: Dan Wang, et al.
Published: (2024-01-01)

Cell therapy for a rare disease- hairy cell leukemia variant
by: Claire Fritz, et al.
Published: (2024-12-01)

In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy
by: Weiyue Zhang, et al.
Published: (2024-11-01)

Choice of activation protocol impacts the yield and quality of CAR T cell product, particularly with older individuals
by: Palak H Mehta, et al.
Published: (2024-01-01)

CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity
by: Yaojie Kong, et al.
Published: (2025-01-01)

Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma
by: Narendranath Epperla, et al.
Published: (2025-01-01)

Regional and intratumoral adoptive T-cell therapy
by: I. Olivera, et al.
Published: (2024-12-01)

CAR-T CELL THERAPY IN LARGE B CELL LYMPHOMA
by: Ugo Testa, et al.
Published: (2023-10-01)

Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors
by: Pierre-Antoine Laurent, et al.
Published: (2023-12-01)

Management of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, followed by an intestinal perforation: a case report
by: G. Menardi, et al.
Published: (2025-01-01)

GD2 targeting CAR T cells for neuroblastoma
by: John Anderson, et al.
Published: (2024-12-01)

CAR-NK cells derived from cord blood originate mainly from CD56−CD7+CD34−HLA-DR−Lin− NK progenitor cells
by: Tansri Wibowo, et al.
Published: (2024-12-01)

Hepatic T cell lymphoma after chimeric antigen receptor T cell therapy for myeloma
by: Joshua Mehr, et al.
Published: (2024-12-01)

Evaluation of Toxicity Associated with CAR-T Cell Therapy and Nursing Interventions
by: Seçkin ERDAL, et al.
Published: (2024-10-01)

LLT1 overexpression renders allogeneic-NK resistance and facilitates the generation of enhanced universal CAR-T cells
by: Shuxian Zhu, et al.
Published: (2025-01-01)

Advances in engineered T cell immunotherapy for autoimmune and other non-oncological diseases
by: Qiaolin Huang, et al.
Published: (2025-02-01)

Hypoimmunogenic CD19 CAR-NK cells derived from embryonic stem cells suppress the progression of human B-cell malignancies in xenograft animals
by: Qi Zhang, et al.
Published: (2024-11-01)

Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects
by: Mehdi Alidadi, et al.
Published: (2024-11-01)